⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 29, 2024Journal of Medical EconomicsOpen Access

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Deborah R. Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frédéric Kinkead Patrick Lefèbvre Dominic Pilon Daniel J. George

View Full Paper

Ask AI

Bookmark

Share

Abstract

Aims: To describe healthcare resource utilization (HRU) and costs of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kaye et al. (2024) studied this question.

synapsesocial.com/papers/68e76d10b6db6435876e30fa https://doi.org/10.1080/13696998.2024.2323901

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States2024 · 10 citations
2Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study2024 · 6 citations
3Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review2025 · 1 citations
4Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen2025 · 1 citations
5Real-world clinical and economic outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerRetrospective Study · 2026

More related papers

The Cost of Metastatic Prostate Cancer in the United States2022
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia2024
Survival outcomes for metastatic castration sensitive prostate cancer: Real world data from a Danish cohort 2016-2022.2024

More from Journal of Medical Economics

Cost‑effectiveness analysis of the mRNA‑1345 RSV vaccine for older adults in ItalyMon,
Morbidity burden and healthcare costs in idiopathic multicentric Castleman disease (BURDEN-iMCD): a retrospective population-level matched cohort analysisSun,